Board of Directors

 
 

Rick Blume

Chairman 

Rick Blume is Managing Director of Excel Venture Management, and he has been financing companies in healthcare for over three decades... Show More

 

Rick co-founded CB Health Ventures in 1998. In addition to Saladax, Rick has served as a director or active investor in many companies including Lantos Technologies, Cytyc (acquired by Hologic - HOLX), AbT (now OSI - OSIP), Somatogen (acquired by Baxter - BAX), EdenTec (acquired by Nellcor), Exact Sciences (EXAS), IPC The Hospitalist Company (IPCM), GeneOhm (acquired by Becton Dickinson - BDX), Zonare, TransMedics, US Servis (acquired by McKesson); and the former public health insurance company Washington National. Rick has been active in initiating and teaching courses in venture capital and entrepreneurship at both Boston College Carroll School of Management and Simmons College School of Management, and serving on the Boards of the Chicago Biomedical Consortium and the National Regenerative Medicine Foundation. Rick did his undergraduate studies at University of the Pacific and Stanford. His MBA is from Stanford University. 

 
 

Salvatore J. Salamone, PhD

President & CEO

Dr. Salamone has more than 30 years’ experience in the health care and medical device industries. Prior to founding Saladax in 2004, Dr. Salamone was Vice President of Research and Development at Roche Diagnostics ... Show More

 

where he was responsible for North American research and development efforts for the Laboratory Systems Division. During his 17-year tenure at Roche, Dr. Salamone’s efforts resulted in the launch of seven major reagent product lines, comprised of more than 70 FDA-approved products and more than 200 instrument applications. Dr. Salamone is recognized globally in the field of drug monitoring, having authored more than 100 publications, including articles, textbook chapters, books, and is also the holder of 39 issued US patents. He is a reviewer for several scientific journals, is often an invited speaker at major scientific conferences, and he sits on an NIH study section for SBIR-STTR grants. Dr. Salamone earned two bachelor’s degrees from Villanova University, a master’s and a PhD degree from Rutgers University and was a Science Engineering Research Council (SERC) Post-Doctoral Fellow at Oxford University.

 
 

Joel Zhang

Director 

Dr. Zhang currently is the president of the Diagnostic Division of Shanghai Fosunpharma (group), a leading company in pharmaceutics, Medical device and IVD business in China.   Show More

 

With 13 years industry experience, Dr. Zhang worked in different areas at Fosunpharma from research and product development, Marketing, operation and management the whole business unit. Dr. Zhang holds the PhD. Of Immunology and MD. Degree from Fudan University, Shanghai Medical School. 

 
 

Guan Xiaohui

Director 

Ms. Xiaohui (关晓晖), has over 15 years experience of financial management experience in the health care industry. She is currently senior vice president and CFO of Shanghai Fosun Pharmaceutical Group Co.  Show More

 

She joined the Fosun Group in 2000 as the Company’s Financial Manager for Retail Pharmaceuticals and held positions of increasing responsibility before being appointed Senior Vice President and CFO in 2015. Ms. Xiaohui serves on several boards for biotechnology and medical oriented companies. She holds a Masters of Accounting from Chinese University of Hong Kong and is a certified public accountant. 

 
 

David M. Brewer

Director 

Dave spent over 35 years in the aluminum industry in management positions with three different companies. He has served in management and senior management positions in manufacturing, planning, marketing, sales and general management... Show More

 

He held various management positions with ARCO Aluminum, a division of Atlantic Richfield, including president of one of their largest divisions. He also represented Norsk Hydro of Norway in their efforts to expand into North America through acquisitions and green field projects in the aluminum industry. He has been with Columbia Aluminum and is successor company Columbia Ventures (CVC) for over 25 years. He has held various management positions including President of trading operations, President of Columbia Aluminum Extrusions and Fabrication, and President & COO of Columbia Aluminum. Since 2006 he has served as Vice Chairman of Columbia Ventures and assisted in its expansion into telecommunications. He currently or previously serves on the boards of CVC; Magnet, I.E in Ireland; Mid Park Manufacturing; One Communications; CTC Communications and non-profits The Home of the Innocents and Kentucky Chapter of the American Diabetes Association.

 
 

Michael Esposito

Director 

Michael Esposito is the President of Norbridge, Inc., a management consulting firm based in Boston.  He undertakes functional and corporate planning assignments for pharmaceutical, biotechnology, medical equipment/supply/device and diagnostics companies around the world. Show More

 

 Mr. Esposito received his MBA from the Amos Tuck School at Dartmouth College (1981) and his BS in Pharmacy from the Massachusetts College of Pharmacy (1978).  Prior to joining Norbridge in 1998, Mr. Esposito was a Vice President at Arthur D. Little and a Marketing Manager at Pfizer, Inc.  

Mr. Esposito was a member of the Board of Directors at Angioblast Systems, Inc. and at Aspect Medical Systems, Inc. prior to their acquisitions.  He is a former Trustee and is now Chairman of the Annual Appeal for the Rotch-Jones-Duff House & Garden Museum.  He is a member of the Board of Trustees of the New Bedford Symphony Orchestra and a member of the Corporation of MCPHS University (formerly The Massachusetts College of Pharmacy and Health Sciences).